Researchers have identified a library of molecules that shut down the SARS-CoV-2 polymerase reaction, a key step that establishes the potential of these molecules as lead compounds to be further modified for the development of COVID-19 therapeutics. Five of these molecules are already FDA-approved for use in the treatment of other viral infections including HIV/AIDS, cytomegalovirus, and hepatitis B.
from Health & Medicine News -- ScienceDaily https://www.sciencedaily.com/releases/2020/06/200630125124.htm
No comments:
Post a Comment